NCT04763759

Phase 1Interventional

Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

View on ClinicalTrials.gov ↗

Timeline

Start date: Feb 8, 2021
Primary completion: Feb 28, 2022
Completion date: Jul 31, 2022
First posted: Feb 21, 2021
Last posted: Oct 5, 2021
Enrollment: 28
Arms / groups: 3 / —
Source: AACT · ingestion pipeline

Sponsors

Trellis Bioscience LLCLead sponsor
Department of Health and Human ServicesCollaborator
Phoenix Clinical Research CenterCollaborator
Phoenix Clinical Research CenterOverall official - principal investigator
LifeBridge HealthCollaborator
LifeBridge HealthOverall official - principal investigator
The University of Texas, DallasCollaborator
The University of Texas, DallasOverall official - principal investigator
University of Alabama, BirminghamCollaborator
University of Alabama, BirminghamOverall official - principal investigator
University of FloridaCollaborator
University of FloridaOverall official - principal investigator
University of Southern CaliforniaCollaborator
University of Southern CaliforniaOverall official - principal investigator
University of VirginiaCollaborator
University of VirginiaOverall official - principal investigator
Wellcome TrustCollaborator
University of Southern CaliforniaOfficial
University of Alabama, BirminghamOfficial
The University of Texas, DallasOfficial
Phoenix Clinical Research CenterOfficial
University of VirginiaOfficial
LifeBridge HealthOfficial
University of California, Los AngelesCollaborator
University of FloridaOfficial
University of California, Los AngelesOfficial

Drugs studied

trl1068

Indications studied

Prosthesis-Related Infections

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.